AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of “Buy” by Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned an average recommendation of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $21.50.

ANGO has been the topic of several analyst reports. Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Tuesday, June 4th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. Finally, TheStreet lowered shares of Upland Software from a “b-” rating to a “c+” rating in a report on Wednesday, July 10th.

AngioDynamics stock traded down $0.03 during midday trading on Friday, reaching $21.51. 1,366 shares of the company’s stock were exchanged, compared to its average volume of 219,032. The firm has a 50-day moving average price of $19.85. The company has a current ratio of 4.30, a quick ratio of 3.75 and a debt-to-equity ratio of 0.20. The company has a market cap of $796.42 million, a price-to-earnings ratio of 26.08 and a beta of 0.69. AngioDynamics has a 52 week low of $18.11 and a 52 week high of $25.48.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The business had revenue of $96.30 million during the quarter, compared to analyst estimates of $92.34 million. During the same quarter in the previous year, the firm posted $0.20 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts expect that AngioDynamics will post 0.27 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its holdings in AngioDynamics by 100.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 1,100 shares during the last quarter. Advisor Group Inc. raised its holdings in AngioDynamics by 21.4% in the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 601 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of AngioDynamics by 28.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 1,181 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of AngioDynamics by 121.9% during the first quarter. BNP Paribas Arbitrage SA now owns 8,883 shares of the medical instruments supplier’s stock valued at $203,000 after purchasing an additional 4,880 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. purchased a new position in shares of AngioDynamics during the first quarter valued at approximately $213,000. 98.47% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: How is the LIBOR rate calculated?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit